|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||109.91 - 113.74|
|52-week range||15.17 - 116.67|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.57|
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
SAN DIEGO, Jan. 02, 2018-- AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis. Announced Positive ANB019 Top-Line Phase 1 Trial Results. Multiple Top-Line Clinical Data Readouts Expected Through the First Half ...
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.